Agenus Upgraded to Buy After 189% Surge Off 12M Low: Analysts Eye $30 Target

For biotech investors, the volatility around clinical-stage names is a double-edged sword. Agenus (AGEN) exemplifies this: after missing Q1 revenue by 74% and EPS by over $1, the stock soared 189% from its trough on pipeline optimism, prompting Wall Street Zen to flip from hold to buy. But with one analyst slashing the target to a sell and another projecting a near 4x return, the divergence underscores the high-stakes nature of early-stage oncology plays.

Wall Street Zen issued a flurry of rating upgrades over the weekend of August 3, 2026, lifting its stance on three companies spanning technology, regional banking, and biotechnology. The simultaneous moves — upgrading F5 (FFIV) from Hold to Buy, First Busey (BUSE) from Sell to Hold, and Agenus (AGEN) from Hold to Buy — come as second-quarter earnings season winds down and analysts recalibrate forward expectations. While each name reflects a distinct sector narrative, the clustering of upgrades from a single research house at a time of mixed macro signals underscores the growing importance of stock-specific fundamentals over broad market themes.

“

Yet the stock has roared back 189% from its 52-week low of $2.71 to $7.82, driven by catalysts like HC Wainwright’s $30 price target (up from $23) and B.

The F5 upgrade is the most straightforward on a fundamental level. The networking technology company reported fiscal third-quarter results on July 27 that crushed estimates: EPS of $4.73 versus the consensus $4.00 on revenue of $865.08 million against an expected $834.60 million. That $0.73 upside surprise and 3.6% revenue beat propelled multiple analyst firms to revise targets. JPMorgan raised its price target to $515 (from $500), Morgan Stanley lifted its objective to $415 (from $380), and Royal Bank of Canada reiterated Outperform. Yet just one day after the earnings release, Zacks Research downgraded the stock from Strong-Buy to Hold, citing valuation concerns, and Needham maintained its Hold. The consensus rating sits at Hold with an average target of $416.62, leaving the stock trading at $406.35 — slightly below the Street’s mean expectation. The disconnect between strong execution and cautious ratings reveals a market weighing F5’s 32.35 P/E multiple and a PEG ratio near 4 against slowing enterprise IT spending. Wall Street Zen’s buy call suggests it sees further upside from application security and multi-cloud tailwinds that haven’t been fully priced in.

First Busey’s upgrade from Sell to Hold is a more incremental shift but carries weight given the severity of the prior pessimistic stance. The Illinois-based regional bank posted a top- and bottom-line beat on July 28, delivering EPS of $0.69 versus the $0.63 estimate. The company has attracted a patchwork of analyst opinions: Zacks Research upgraded it to Strong-Buy on July 21, while Keefe, Bruyette & Woods raised its target to $34 (Outperform) and Stephens lifted to $28 (Equal Weight). The consensus now reads Moderate Buy with a $32.00 target against a $31.27 share price. With a modest 12.92 P/E and low 0.12 debt-to-equity ratio, First Busey represents a value play in an environment where many regional banks are navigating commercial real estate exposure. Wall Street Zen’s move from Sell to Hold indicates that worst-case scenarios have receded, but full-blown conviction remains elusive.